FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1371-1372 November 17, 1994 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Finding the optimal treatment for patients with candidemia has been a major source of frustration for physicians during the past decade. It is a tremendous challenge, since the infection is often an obstacle to successful therapy, and the cost in terms of health resources is high. The rate of candidemia has increased by more than 400 percent since the early 1980s, and candidemia currently accounts for 10 to 15 percent of hospital-acquired infections of the bloodstream.¹ There is an increased awareness of the morbidity, mortality, and economic burden associated with candidemia in various groups of patients, including those without neutropenia. . . . [Full Text of this Article]

References

This article has been cited by other articles:

• DiNubile, M. J., Girmenia, C., Martino, P., Cofsky, R. D., Tang, C.M., Howe, P., Crook, D.W., Rex, J. H., Bennett, J. E., Sugar, A. M., Meunier, F. (1995). The Treatment of Candidemia. NEJM 332: 1100-1102 [Full Text]